The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target
was a major breakthrough for the treatment of highly aggressive HER2-positive breast …

Abstract Antibody–drug conjugates (ADCs), a class of targeted cancer therapeutics
combining monoclonal antibodies with a cytotoxic payload via a chemical linker, have …

Trastuzumab deruxtecan is an antibody–drug conjugate with high extracranial activity in
human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. We …

Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or
retrospective patient cohorts with human epidermal growth factor receptor 2–positive …

Abstract DESTINY-Breast01 (NCT03248492) evaluated trastuzumab deruxtecan (T-DXd; DS-
8201) in patients with heavily pretreated HER2-positive metastatic breast cancer (mBC). We …

Epigenetic modifications of chromatin, including histone acetylation, and tumor
angiogenesis play pivotal roles in creating an immunosuppressive tumor microenvironment …

Purpose: Brain metastases can occur in up to 50% of patients with metastatic HER2-positive
breast cancer. Because patients with active brain metastases were excluded from previous …

Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …

The identification of the HER2 alteration as an actionable oncogenic driver in breast cancer
has propelled the development of HER-targeting monoclonal antibodies (mAb) such as …

Antibody-drug conjugates (ADCs) represent an important class of cancer therapies that have
revolutionized the treatment paradigm of solid tumors. To date, many ongoing studies of …